Proactive Investors - Run By Investors For Investors

Amryt Pharma given permission to extend age eligibility for drug trial

Amryt is developing AP101 as a potential treatment for Epidermolysis Bullosa, where skin blisters to the touch
baby
The condition is often present from birth

Amryt Pharma PLC (LON:AMYT) said it has been given permission to extend the age eligibility for its Phase III trial of a drug to treat a rare skin condition.

The study’s independent data monitoring committee has concluded that children aged between 21 days and four years can take part in the programme.

READ: Amryt Pharma adds new element to promising portfolio

Amryt is developing AP101 as a potential treatment for Epidermolysis Bullosa, where skin blisters to the touch.

The company’s chief executive, Joe Wiley, called the committee’s decision “a significant step forward”, adding it could help address an unmet need for a devastating condition, often present from birth.

“This development represents another milestone for Amryt as we build on our vision of becoming a global leader in rare and orphan diseases," he went on.

In a note to clients, analysts at ‘house’ broker Shore Capital said the update “demonstrates continued momentum at Amryt, following the significant positive interim efficacy update” at the start of January.

They added; “We continue to view Amryt as a compelling investment opportunity to gain exposure to a diversified rare disease platform, with a marketed drug for an ultra-rare disease, a further de-risked Phase III asset in an untapped $1bn market opportunity, and an attractive pre-clinical gene therapy platform.

“Our risk-adjusted sum-of-the-parts valuation suggests Lojuxta alone is worth c.20p/share, with the Phase III EB asset and early-stage pipeline not reflected.”

In early afternoon trading, Amryt Pharma shares were 0.3% higher at 15.55p.

 -- Adds analyst comment, share price --

View full AMYT profile View Profile

Amryt Pharma PLC Timeline

Related Articles

patch
Sun
The New Jersey company's lead product is Twirla, a low-dose prescription contraceptive applied once weekly for three weeks, followed by a week without the patch
Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use